ストックスクリーナーアプリを入手
8.2842
1.64%
0.1342
前日終値:
$8.15
開ける：
$8.25
24時間の取引高:
27,310
Relative Volume:
0.13
時価総額：
$456.13M
収益：
$79.55M
当期純損益:
$-37.25M
株価収益率:
-11.74
EPS:
-0.7054
ネットキャッシュフロー:
$-25.40M
1週間 パフォーマンス:
+1.76%
1か月 パフォーマンス:
+68.71%
6か月 パフォーマンス:
+53.40%
1年 パフォーマンス:
+101.06%
1日の値動き範囲:
$8.05
$8.29
1週間の範囲:
$7.89
$8.85
52週間の値動き範囲:
$3.19
$9.2362
Sight Sciences Inc Stock (SGHT) Company Profile
Compare SGHT vs ABT, SYK, MDT, BSX, EW
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SGHT
Sight Sciences Inc
|
8.28 | 466.60M | 79.55M | -37.25M | -25.40M | -0.7054 |
ABT
Abbott Laboratories
|
116.11 | 198.01B | 46.59B | 5.41B | 7.38B | 3.0938 |
SYK
Stryker Corp
|
330.13 | 130.41B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
93.28 | 120.48B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
50.52 | 75.37B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
90.31 | 53.19B | 6.30B | 1.07B | 1.09B | 1.8406 |
Sight Sciences Inc Stock (SGHT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-05 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2025-08-08 | アップグレード | Lake Street | Hold → Buy |
| 2024-12-06 | 開始されました | UBS | Buy |
| 2024-11-04 | ダウングレード | Lake Street | Buy → Hold |
| 2024-08-21 | 開始されました | Lake Street | Buy |
| 2023-09-12 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2023-09-12 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2023-09-12 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2023-08-24 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2023-07-10 | ダウングレード | Citigroup | Buy → Neutral |
| 2023-01-06 | アップグレード | Stifel | Hold → Buy |
| 2022-10-04 | 開始されました | Needham | Hold |
| 2022-07-26 | 開始されました | Stifel | Hold |
| 2022-02-03 | 開始されました | William Blair | Outperform |
| 2022-01-07 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
すべてを表示
Sight Sciences Inc (SGHT) 最新ニュース
FDA Broadens ‘Indications for Use’ for Sight Sciences’ TearCare System - VisionMonday.com
Sight Sciences Announces FDA Expanded Indication for TearCare to Improve Meibomian Gland Function in Evaporative Dry Eye Disease - Quiver Quantitative
GSA Capital Partners LLP Makes New Investment in Sight Sciences, Inc. $SGHT - MarketBeat
FDA recalls over 39K bottles of CLEAR EYES Maximum Itchy Relief drops - Glance by Eyes On Eyecare
A Quick Look at Today's Ratings for Sight Sciences(SGHT.US), With a Forecast Between $8 to $12 - Moomoo
Sight Sciences Earnings Call Shows Growth And Discipline - TipRanks
Sight Sciences (NASDAQ: SGHT) holder to sell 12,014 shares - Stock Titan
Sight Sciences Inc (NASDAQ: SGHT) Share Price, SGHT Stock News, SGHT Share Price & Updates - Kalkine
Sight Sciences (SGHT) Pulls Back to $8.14: Range-Bound Move Tests Key Support ZoneVol Target Rebalance - Vinanet
Sight Sciences (SGHT) insider plans 48,000-share stock sale after option exercise - Stock Titan
SGHT (SGHT) holder files to sell 2,500 shares after stock vesting - Stock Titan
Sight Sciences (SGHT) Q2 2026 Earnings Call Transcript - AOL.com
SGHT insider Jeremy Hayden files Form 144 for recent and planned stock sales - Stock Titan
SGHT Q2 2026 Earnings: Narrowed Loss Beats Estimates, Shares Jump 6.49%Earnings Turnaround - Vinanet
SGHT (NASDAQ: SGHT) insider Jeremy Hayden plans $165,878 stock sale - Stock Titan
Sight Sciences appoints Kashif Rashid as chief legal officer, Jeremy Hayden to step down By Investing.com - Investing.com Australia
Sight Sciences Names Kashif Rashid as New Chief Legal Officer Amid Leadership Change - Kalkine Media
Sight Sciences names Kashif Rashid chief legal officer, replacing Jeremy Hayden - Bitget
Sight Sciences Appoints New Chief Legal Officer Rashid - tipranks.com
Sight Sciences appoints Kashif Rashid as chief legal officer, Jeremy Hayden to step down - Investing.com Nigeria
Form 8K Sight Sciences Inc For: 10 August By Investing.com - Investing.com Nigeria
Sight Sciences(SGHT) Stock Options Chain | Quotes & News - Moomoo
Sight Sciences Reports Second Quarter 2025 Financial Results and Raises Full Year 2025 Revenue Guidance - 富途牛牛
Sight Sciences (NASDAQ:SGHT) Rating Increased to Buy at Wall Street Zen - MarketBeat
Analysts Offer Insights on Healthcare Companies: Pfizer (PFE) and Sight Sciences (SGHT) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Immuneering (IMRX), Revolution Medicines (RVMD) and Sight Sciences (SGHT) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Zimmer Biomet Holdings (ZBH), Cytek Biosciences (CTKB) and Sight Sciences (SGHT) - The Globe and Mail
UBS Group Forecasts Strong Price Appreciation for Sight Sciences (NASDAQ:SGHT) Stock - MarketBeat
UBS Adjusts Price Target on Sight Sciences to $8 From $7, Maintains Buy Rating - marketscreener.com
Sight Sciences, Inc. Stock 12‑Month Price Target Raised to $8.6, Implies 55% Upside - TradingView
Sight Sciences Q2 Earnings Call Highlights - MarketBeat
Sight Sciences Sees Q2 Revenue Growth, Raises 2026 Guidance - VisionMonday.com
Sight Sciences (NASDAQ:SGHT) Posts Earnings Results, Beats Estimates By $0.10 EPS - MarketBeat
Sight Sciences (SGHT) Stock Sees Modest Fair Value Cut As Analysts Revisit Guidance - Yahoo Finance
Earnings call transcript: Sight Sciences raises 2026 outlook on Q2 growth, shares fall - Investing.com Nigeria
Sight Sciences, Inc. reports results for the quarter ended June 30Earnings Summary - tradingview.com
Sight Sciences : Reports Second Quarter 2026 Financial Results - marketscreener.com
Sight Sciences wins FDA clearance for Omni Surgical System - MassDevice
Sight Sciences, Inc. (SGHT) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Sight Sciences (SGHT) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates - Yahoo Finance
Aetna covers Sight Sciences glaucoma devices for commercial plans By Investing.com - Investing.com South Africa
Sight Sciences Q2 revenue rises 20%, beats estimates - TradingView
Aetna covers Sight Sciences glaucoma devices for commercial plans - Investing.com
Sight Sciences, Inc. Provides Earnings Guidance for the Third Quarter of 2026 - marketscreener.com
Sight Sciences, Inc. Q2 2026: Revenue $23.39M, EPS $(0.08) — 10-Q Summary - TradingView
Sight Sciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Sight Sciences (NASDAQ: SGHT) lifts 2026 outlook after 20% Q2 growth - Stock Titan
Sight Sciences Reports Second Quarter 2026 Financial Results - The Manila Times
Sight Sciences Announces Aetna Coverage for OMNI and SION Surgical Systems - The Manila Times
BRIEF-Sight Sciences Q2 Revenue USD 23.4 Million Vs. IBES Estimate USD 21.7 Million - TradingView
Sight Sciences publishes investor presentation on interventional glaucoma, dry eye platforms - Bitget
Sight Sciences Inc (SGHT) 財務データ
収益
当期純利益
現金流量
EPS
0.76%
大文字化:
|
ボリューム (24 時間):